EZH2在非小细胞肺癌中的表达及临床意义  

EXPRESSION OF EZH2 IN NON-SMALL CELL LUNG CANCER AND ITS CLINICAL SIGNIFICATION

作　　者：张嘉玲[1] 苏秀兰[1] 林华型[2] 贾永峰[3] 毕勇毅[2] 呼群[1] 

机构地区：[1]内蒙古医科大学附属医院临床医学研究中心,内蒙古呼和浩特010050 [2]武汉大学公共卫生学院 [3]内蒙古医科大学病理科

出　　处：《内蒙古医科大学学报》2013年第1期12-16,共5页Journal of Inner Mongolia Medical University

基　　金：国家自然科学基金项目(81160253);内蒙古自治区自然科学基金项目(2009bs1107)

摘　　要：目的:探讨EZH2在非小细胞肺癌细胞系及临床病理组织中的表达及意义。方法:利用RT-PCR方法及免疫组织化学染色方法,检测14株人非小细胞肺癌细胞及84例早期非小细胞肺癌病理组织中EZH2表达,并分析EZH2表达与病理组织类型和临床病理特征的相关性。结果:80%的非小细胞肺癌细胞株中EZH2mRNA较正常肺组织呈高表达;84例非小细胞肺癌组织中EZH2蛋白呈高表达者55例(占65.5%),呈不表达者29例(占34.5%);Kaplan-Meier和Log-rank分析结果显示EZH2高表达病人的中位生存期显著短于EZH2不表达病人,P值=0.027,具有统计学意义。结论:EZH2异常表达可能是促进非小细胞肺癌的发生的重要因素之一,EZH2表达可作为非小细胞肺癌预后判断的潜在分子标记物。同时开展EZH2研究可为肺癌的个体化治疗提供新的前景。Objective ： to elucidate the role of EZH2 in non-small cell lung cancer（ NSCLC ） by in- vestigating both clinical samples and cell lines. Methods：We performed RT-PCR and an immunohisto- chemical analysis of EZH2 expression in 14 NSCLC cell lines and to investigate the association of its expression level with clinic pathological variables in early stage of 84 NSCLC tissues. Results ： EZH2 mRNA was increased in 80% NSCLC cell lines compared with normal human lung tissue. The immuno- histoehemical analysis classified NSCLC samples（ n = 84 ） into a negative EZH2 expression group （ n = 29 ;34.5% ） and a positive EZH2 expression group （ n = 55 ; 65.5% ）. Kaplan-Meier survival analysis and log-rank test demonstrated that patients whose samples were classified into the positive EZH2 expression group had a significantly shorter overall survival than no EZH2 expression （P = 0. 027 ）.Conclusions：Abnormal expression of EZH2 gene is one of key molecules to promote progression of NSCLC. EZH2 is a novel predictive marker of cancer progression. Studies on EZH2 should provide a novel perspective on personalized cancer therapies.

关 键 词：EZH2 非小细胞肺癌 分子标记物 预后 

分 类 号：R734.2[医药卫生—肿瘤]